We’ve been busy, and we want you to know what we’re up to.
Take a look at the latest news from Jaguar Gene Therapy.
Take a look at the latest news from Jaguar Gene Therapy.
In the news.
Kate Neer
Vice President, Corporate Communications and Patient Advocacy
kneer@jaguargenetherapy.com
(815) 978-3891
Jim Goff
Vice President, Investor Relations
jgoff@jaguargenetherapy.com
(224) 340-0237
“Jaguar is uniquely positioned to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases.”
“I am confident that our team’s experience with the proven and reliable AAV9 platform will minimize development risk and enable us to accelerate the availability of life-changing therapies to patients, caregivers and their families.”
“Patient safety is our top priority, and our state-of-the-art manufacturing facility will give us greater control of the manufacturing process to better ensure the highest purity level of our products.”
• The company recently conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) and is cleared to proceed with dosing of pediatric patients (2+ years) with JAG201 with expansion into adults (18+ years) following the pediatric cohort • The first gene therapy clinical trial to evaluate therapeutic impact in a genetic […]
LAKE FOREST, Illinois – January 31, 2024 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).
ALBANY, N.Y., and LAKE FOREST, Ill., July 25, 2022 – The Galactosemia Foundation, a non-profit charitable organization that advocates for people with galactosemia and their families, and Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the publication of Navigating Galactosemia Life Stages: A Handbook for the Galactosemia Community.
LAKE FOREST, Ill., May 16, 2022 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced results of two preclinical studies of JAG101 in two different animal models of Type 1 galactosemia. Results showed that low and high doses of intravenous JAG101 given as a one-time gene replacement therapy reduced levels of toxic metabolites in brain and liver tissues and increased GALT enzyme expression and activity in tissues relevant to long-term outcomes in Type 1 galactosemia.
LAKE FOREST, Ill., May 2, 2022 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced two abstracts related to its JAG101 Type 1 galactosemia program will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which is taking place at the Walter E. Washington Convention Center in Washington, D.C., from May 16-19.
LAKE FOREST, Ill., March 29, 2022 –(BUSINESS WIRE)–Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases including those that impact sizeable patient populations, today announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes (T1D), have invested in the company.
LAKE FOREST, Ill., Dec. 14, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for sizeable patient populations suffering from severe genetic diseases, today announced additional details, including target genes, for its initial preclinical pipeline programs: JAG101 for Type 1 galactosemia; JAG201 for a genetic cause of autism spectrum disorder (ASD) and Phelan-McDermid syndrome and other severe neurodevelopmental disorders with a SHANK3 mutation or deletion; and JAG301 for Type 1 diabetes.
LAKE FOREST, Ill., Oct. 26, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for larger patient populations suffering from severe genetic diseases, today announced plans for a commercial manufacturing facility in Durham, North Carolina.
LAKE FOREST, Ill., April 13, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, today announced it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management.
LAKE FOREST, Ill. (Feb. 25, 2021) – Jaguar Gene Therapy launched today after being in stealth mode for the past year and is uniquely positioned to accelerate gene therapy development. Led by the former AveXis leadership and resourced by Deerfield Management
"*" indicates required fields
Jaguar Gene Therapy to Initiate Inaugural Pediatric Clinical Trial Targeting a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
/in Featured, News, Press Release/by Kate Neer• The company recently conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) and is cleared to proceed with dosing of pediatric patients (2+ years) with JAG201 with expansion into adults (18+ years) following the pediatric cohort • The first gene therapy clinical trial to evaluate therapeutic impact in a genetic […]
Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
/in Featured, Press Release/by Kate NeerLAKE FOREST, Illinois – January 31, 2024 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).
New Resource for the Galactosemia Community Launches to Empower Families as They Navigate Lifelong Genetic Disease
/in Featured, Press Release/by Hayleigh NolanALBANY, N.Y., and LAKE FOREST, Ill., July 25, 2022 – The Galactosemia Foundation, a non-profit charitable organization that advocates for people with galactosemia and their families, and Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the publication of Navigating Galactosemia Life Stages: A Handbook for the Galactosemia Community.
Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting
/in Featured, Press Release/by David AndersonLAKE FOREST, Ill., May 16, 2022 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced results of two preclinical studies of JAG101 in two different animal models of Type 1 galactosemia. Results showed that low and high doses of intravenous JAG101 given as a one-time gene replacement therapy reduced levels of toxic metabolites in brain and liver tissues and increased GALT enzyme expression and activity in tissues relevant to long-term outcomes in Type 1 galactosemia.
Jaguar Gene Therapy Announces Preclinical Data Presentations at Upcoming American Society of Gene and Cell Therapy 25th Annual Meeting
/in Featured, Press Release/by eallisonLAKE FOREST, Ill., May 2, 2022 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced two abstracts related to its JAG101 Type 1 galactosemia program will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which is taking place at the Walter E. Washington Convention Center in Washington, D.C., from May 16-19.
Jaguar Gene Therapy Announces Samsung and JDRF T1D Fund as New Investors
/in Featured, Press Release/by David AndersonLAKE FOREST, Ill., March 29, 2022 –(BUSINESS WIRE)–Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases including those that impact sizeable patient populations, today announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes (T1D), have invested in the company.
Jaguar Gene Therapy Announces Target Genes for Initial Pipeline Programs in Severe Genetic Diseases
/in Featured, Press Release/by David AndersonLAKE FOREST, Ill., Dec. 14, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for sizeable patient populations suffering from severe genetic diseases, today announced additional details, including target genes, for its initial preclinical pipeline programs: JAG101 for Type 1 galactosemia; JAG201 for a genetic cause of autism spectrum disorder (ASD) and Phelan-McDermid syndrome and other severe neurodevelopmental disorders with a SHANK3 mutation or deletion; and JAG301 for Type 1 diabetes.
Jaguar Gene Therapy Announces State-of-the-Art Gene Therapy Commercial Manufacturing Facility in North Carolina
/in Featured, Press Release/by David AndersonLAKE FOREST, Ill., Oct. 26, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for larger patient populations suffering from severe genetic diseases, today announced plans for a commercial manufacturing facility in Durham, North Carolina.
Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management
/in Featured, Press Release/by David AndersonLAKE FOREST, Ill., April 13, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, today announced it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management.